Demethyleneberberine

Modify Date: 2024-01-03 16:22:04

Demethyleneberberine structure	Common Name	Demethyleneberberine
	CAS Number	25459-91-0	Molecular Weight	323.34300
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₉H₁₈NO₄+	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Demethyleneberberine

Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD)[1][2][3].

Name	9,10-dimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-2,3-diol
Synonym	More Synonyms

Description	Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD)[1][2][3].
Related Catalog	Signaling Pathways >> Epigenetics >> AMPK Research Areas >> Inflammation/Immunology Signaling Pathways >> PI3K/Akt/mTOR >> AMPK Research Areas >> Metabolic Disease
References	[1]. Zhang P, et al. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther. 2015 Jan;352(1):139-47. [2]. Chen YY, et al. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflamm Res. 2017 Feb;66(2):187-196. [3]. Qiang X, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016 Apr 15;472(4):603-9.

Description

Related Catalog

Signaling Pathways >> Epigenetics >> AMPK

Research Areas >> Inflammation/Immunology

Signaling Pathways >> PI3K/Akt/mTOR >> AMPK

Research Areas >> Metabolic Disease

References

[1]. Zhang P, et al. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther. 2015 Jan;352(1):139-47.

[2]. Chen YY, et al. Demethyleneberberine alleviates inflammatory bowel disease in mice through regulating NF-κB signaling and T-helper cell homeostasis. Inflamm Res. 2017 Feb;66(2):187-196.

[3]. Qiang X, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016 Apr 15;472(4):603-9.